drugset / Trial / NCT04016740

The PATHFINDER Study: A Feasibility Trial

NCT04016740

Phase 0 Completed 22 enrolled Beth Israel Deaconess Medical Center
Non-randomizedSequentialOpen-labelOther

Summary

The main purpose of this study is to determine whether a rational strategy of EEG guided multimodal general anesthesia using target specific sedative and analgesics could result in enhanced recovery after anesthesia and surgery, decrease in postoperative delirium, and decrease in long term postoperative cognitive dysfunction up to 6 months following cardiac surgery.

Timeline

Start
2019-08-20
Primary completion
2020-02-19
Completion
2020-07-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Dexmedetomidine Other / unclassified 0.2 ug/kg Intravenous
Background Dexmedetomidine Other / unclassified 1 ug/kg Intravenous
Background Dexmedetomidine Other / unclassified 1.4 ug/kg Intravenous
Background Ketamine Small molecule 0.06 mg/kg Intravenous
Background Ketamine Small molecule 0.12 mg/kg Intravenous
Background Propofol Small molecule
Background Remifentanil Small molecule 0.05 ug/kg Intravenous
Background Remifentanil Small molecule 0.2 ug/kg Intravenous
Background Rocuronium Other / unclassified
Background Ropivacaine Other / unclassified 20 ml Other
Background Sevoflurane Other / unclassified Inhaled